Applied Filters
LSIPR, Gowling WLG team up for biologics survey
Life Sciences IP Review has partnered with international law firm Gowling WLG to launch the Patent Litigation Survey to appraise the patent trends in biologics, biosimilars and next generation therapies.
Japan’s IP office upholds CRISPR patent and allows third
A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
SCOTUS declines patents review on Enbrel drug
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
WHO urges vigilance against fake COVID-19 vaccines
The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.
Pyxis secures ADC licence from Pfizer
Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Medical tech leads 2020 innovation at the EPO
Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.
China must protect seed IP to spur investment, warns Sinochem
China must safeguard IP in the seed industry to ensure innovation within the sector, the group chairman of Chinese multinational Sinochem, Frank Ning, has warned.
Five minutes with… Penny Gilbert
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.
A deep dive into Regeneron v Kymab
On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Puma and CANBridge cancel licensing deal for $20m
Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.
